Stock listing
gettex:2H0 Exicure, Inc. Aktie
German listing (gettex) of Exicure, Inc. · home listing NASDAQ:XCUR
Follow Exicure, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:XCUR
$0.90 USD -0.14 (-13.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:XCUR
- Day range
- $0.90 – $1.00 USDNov 20, 2026
- Volume
- 32,146 sharesNov 20, 2026
- Market cap
- $5.89M USDAt the close on Nov 20, 2026 · price × 6.55M shares outstanding
- 52-week range
- $0.778 – $9.48 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $62,689 USDMedian day 21,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:XCUR · Home | $0.90 USD | -0.14 (-13.5%) | 32,146 | $1.00 | $1.00 | $0.90 | $1.04 | Close on Nov 20, 2026 |
| Frankfurt:2H0 | €0.71 EUR | -0.11 (-13.4%) | — | €0.84 | €0.84 | €0.71 | €0.82 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XCUR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.90 | -0.14 | -13.5% | $1.00 | $1.00 | $0.90 | 32,146 | |
| $1.04 | -0.04 | -3.7% | $1.02 | $1.079 | $1.01 | 3,969 | |
| $1.08 | +0.01 | +0.9% | $1.051 | $1.08 | $1.015 | 19,237 | |
| $1.07 | -0.01 | -0.9% | $1.07 | $1.12 | $1.00 | 10,608 | |
| $1.08 | +0.02 | +1.9% | $1.02 | $1.08 | $1.02 | 6,474 | |
| $1.06 | -0.05 | -4.5% | $1.085 | $1.10 | $0.985 | 16,321 | |
| $1.11 | +0.03 | +2.8% | $1.02 | $1.11 | $1.00 | 77,132 | |
| $1.08 | +0.19 | +21.3% | $0.92 | $1.19 | $0.778 | 895,699 | |
| $0.89 | -0.06 | -6.3% | $0.95 | $0.95 | $0.861 | 38,938 | |
| $0.95 | +0.06 | +6.7% | $0.89 | $0.95 | $0.856 | 17,582 | |
| $0.89 | -0.103 | -10.3% | $0.91 | $0.952 | $0.89 | 24,154 | |
| $0.993 | -0.017 | -1.7% | $0.97 | $1.00 | $0.89 | 18,349 | |
| $1.01 | -0.01 | -1.0% | $1.01 | $1.03 | $1.00 | 15,858 | |
| $1.02 | +0.01 | +1.0% | $1.03 | $1.06 | $0.97 | 31,356 | |
| $1.01 | +0.075 | +8.0% | $0.944 | $1.06 | $0.944 | 28,127 | |
| $0.935 | -0.082 | -8.0% | $1.05 | $1.09 | $0.90 | 41,350 | |
| $1.017 | -0.054 | -5.0% | $1.08 | $1.13 | $1.01 | 24,691 | |
| $1.07 | -0.02 | -1.8% | $1.095 | $1.095 | $1.04 | 12,325 | |
| $1.09 | +0.04 | +3.8% | $1.06 | $1.09 | $1.02 | 35,998 | |
| $1.05 | -0.08 | -7.1% | $1.10 | $1.14 | $1.04 | 61,200 | |
| $1.13 | +0.12 | +11.9% | $1.15 | $1.28 | $1.08 | 440,000 | |
| $1.01 | +0.011 | +1.1% | $0.984 | $1.05 | $0.971 | 40,600 | |
| $0.999 | -0.031 | -3.0% | $1.11 | $1.11 | $0.99 | 43,800 | |
| $1.03 | -0.09 | -8.0% | $1.12 | $1.30 | $1.029 | 69,100 | |
| $1.12 | 0.00 | 0.0% | $1.214 | $1.214 | $1.08 | 32,700 | |
| $1.12 | -0.09 | -7.4% | $1.21 | $1.24 | $1.10 | 20,600 | |
| $1.21 | +0.06 | +5.2% | $1.16 | $1.26 | $1.16 | 28,300 | |
| $1.15 | +0.06 | +5.5% | $1.12 | $1.21 | $1.09 | 27,800 | |
| $1.09 | +0.04 | +3.8% | $1.09 | $1.10 | $1.06 | 15,200 | |
| $1.05 | +0.05 | +5.0% | $0.95 | $1.10 | $0.936 | 316,500 | |
| $1.00 | -0.02 | -2.0% | $0.99 | $1.05 | $0.99 | 14,800 | |
| $1.02 | -0.06 | -5.6% | $1.04 | $1.04 | $1.00 | 9,200 | |
| $1.08 | +0.01 | +0.9% | $1.11 | $1.11 | $1.07 | 7,300 | |
| $1.07 | -0.08 | -7.0% | $1.14 | $1.19 | $1.07 | 17,700 | |
| $1.15 | -0.03 | -2.5% | $1.17 | $1.18 | $1.15 | 5,300 | |
| $1.18 | -0.01 | -0.8% | $1.17 | $1.18 | $1.11 | 4,400 | |
| $1.19 | +0.05 | +4.4% | $1.279 | $1.279 | $1.123 | 19,900 | |
| $1.14 | -0.095 | -7.7% | $1.195 | $1.195 | $1.14 | 29,300 | |
| $1.235 | +0.015 | +1.2% | $1.23 | $1.235 | $1.17 | 2,600 | |
| $1.22 | -0.01 | -0.8% | $1.22 | $1.23 | $1.21 | 3,200 | |
| $1.23 | -0.01 | -0.8% | $1.24 | $1.28 | $1.215 | 22,900 | |
| $1.24 | -0.05 | -3.9% | $1.25 | $1.29 | $1.23 | 9,300 | |
| $1.29 | +0.03 | +2.4% | $1.30 | $1.30 | $1.21 | 17,100 | |
| $1.26 | +0.03 | +2.4% | $1.24 | $1.34 | $1.21 | 32,100 | |
| $1.23 | -0.12 | -8.9% | $1.33 | $1.40 | $1.23 | 40,000 | |
| $1.35 | +0.02 | +1.5% | $1.36 | $1.419 | $1.285 | 10,300 | |
| $1.33 | +0.02 | +1.5% | $1.26 | $1.36 | $1.22 | 21,200 | |
| $1.31 | -0.06 | -4.4% | $1.285 | $1.325 | $1.27 | 17,600 | |
| $1.37 | -0.03 | -2.1% | $1.35 | $1.405 | $1.33 | 13,900 | |
| $1.40 | +0.03 | +2.2% | $1.40 | $1.43 | $1.341 | 10,500 | |
| $1.37 | -0.06 | -4.2% | $1.41 | $1.41 | $1.255 | 29,700 | |
| $1.43 | +0.02 | +1.4% | $1.45 | $1.60 | $1.37 | 221,400 | |
| $1.41 | +0.16 | +12.8% | $1.31 | $1.54 | $1.31 | 83,800 | |
| $1.25 | +0.02 | +1.6% | $1.23 | $1.28 | $1.22 | 16,800 | |
| $1.23 | -0.06 | -4.7% | $1.30 | $1.301 | $1.22 | 21,700 | |
| $1.29 | -0.01 | -0.8% | $1.24 | $1.32 | $1.23 | 15,100 | |
| $1.30 | -0.01 | -0.8% | $1.28 | $1.30 | $1.23 | 16,600 | |
| $1.31 | +0.02 | +1.6% | $1.31 | $1.35 | $1.285 | 21,800 | |
| $1.29 | -0.12 | -8.5% | $1.40 | $1.40 | $1.29 | 18,900 | |
| $1.41 | +0.15 | +11.9% | $1.28 | $1.46 | $1.28 | 102,100 | |
| $1.26 | +0.07 | +5.9% | $1.19 | $1.29 | $1.19 | 29,700 | |
| $1.19 | +0.04 | +3.5% | $1.15 | $1.23 | $1.13 | 19,200 | |
| $1.15 | 0.00 | 0.0% | $1.15 | $1.20 | $1.08 | 28,800 | |
| $1.15 | -0.15 | -11.5% | $1.32 | $1.32 | $1.05 | 151,700 | |
| $1.30 | -0.15 | -10.3% | $1.44 | $1.45 | $1.30 | 39,000 |
Splits
2 splits since 2022 · NASDAQ:XCUR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- gettex:2H0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Exicure Announces Strategic Expansion into Parkinson’s Disease
Latest news
Exicure Announces Strategic Expansion into Parkinson’s Disease
Nov 20, 2026
Closed $0.90 (-13.5%) on Nov 20, 2026
Exicure Announces Filing of Notification of Late Filing on Form 12b-25
Nov 16, 2026
Closed $1.08 (+0.9%) on Nov 17, 2026
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
Nov 10, 2026
Closed $1.08 (+21.3%) on Nov 10, 2026
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
Sep 16, 2026
Closed $1.33 (+1.5%) on Sep 16, 2026
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Aug 3, 2026
Closed $1.58 (-1.3%) on Aug 3, 2026
Exicure Announces Board and Committee Changes
Jun 30, 2026
Closed $2.08 (-5.5%) on Jun 30, 2026
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Jun 10, 2026
Closed $2.82 (+2.2%) on Jun 11, 2026
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Jun 1, 2026
Closed $3.11 (-6.6%) on Jun 2, 2026
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Apr 22, 2026
Closed $3.64 (+0.1%) on Apr 23, 2026
Exicure, Inc. Reports Full Year 2025 Financial Results
Mar 25, 2026
Closed $4.61 (0.0%) on Mar 26, 2026
Exicure, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 120 in all · newest Nov 20, 2026 · oldest 2019
- Decks
- 6 decks · latest Jan 5, 2022
Where Exicure, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:XCUR · Home listing | NASDAQ | United States | USD |
| Munich:2H0 | Munich | Germany | EUR |
| LS Exchange:A40L5C | LS Exchange | Germany | EUR |
| BOATS:XCUR | BOATS | United States | USD |
| Lang & Schwarz:A40L5C | Lang & Schwarz | Germany | EUR |
| gettex:2H0 · This page | gettex | Germany | EUR |
| Frankfurt:2H0 | Frankfurt | Germany | EUR |
| Stuttgart:2H0 | Stuttgart | Germany | EUR |
| Tradegate:2H0 | Tradegate | Germany | EUR |
Valuation
Price/book 3.1× against a median of 1.0×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.67M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Tempest Therapeutics, Inc. · NASDAQ:TPST | US$5.74M | US$4.84M | n/a | n/a | n/a | n/a | n/a | n/a | 1.09 |
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Median of the others | US$5.96M | US$4.71M | 0.0× | 191× | 1.0× | 0.0× | 1.00 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 20, 2026 | |
| Q2 2026 | Aug 14, 2026 | +5.3% |
| Q3 2025 | Nov 7, 2025 | −8.9% |
| Q2 2025 | Aug 8, 2025 | +3.0% |
| Q1 2025 | Jun 4, 2025 · After close | −2.5% |
| Q4 2024 | Mar 20, 2025 | +8.9% |
| Q3 2024 | Nov 15, 2024 | +23.9% |
| Q2 2024 | Aug 13, 2024 · After close | −25.6% |
| Q1 2024 | Jun 17, 2024 · After close | +4.7% |
| Q4 2023 | Mar 7, 2024 | −0.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 16, 2023 | +3.5% |
| Q2 2023 | Aug 11, 2023 · After close | −2.6% |
| Q4 2022 | Mar 27, 2023 · After close | −10.8% |
| Q3 2022 | Nov 14, 2022 · After close | −8.7% |
| Q2 2022 | Aug 15, 2022 · After close | −3.5% |
| Q1 2022 | May 16, 2022 · After close | +9.2% |
| Q4 2021 | Mar 25, 2022 · After close | −24.1% |
| Q3 2021 | Nov 19, 2021 · Before open | −30.1% |
| Quarter to Jun 30, 2021 | Aug 12, 2021 · Before open | +3.4% |
| Quarter to Mar 31, 2021 | May 12, 2021 · After close | −8.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2022) | Investor deck | 23 slides | Jan 5, 2022 |
| Investor Presentation (August 2021) | Investor deck | 42 slides | Aug 5, 2021 |
| Investor Presentation (April 2021) | Investor deck | 39 slides | Apr 9, 2021 |
| Investor Day (January 2021) | Investor day | 72 slides | Jan 7, 2021 |
| Technical Presentation (September 2020) | Technical | 91 slides | Sep 16, 2020 |
| Corporate Update (June 2019) | Corporate update | 13 slides | Jun 27, 2019 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of shares of common stock Closed: US$8.7M raised Use of proceeds: Mainly the acquisition of GPCR USA, clinical trial costs and ongoing operations | Dec 26, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 500.0K | 0 | 28.8M | -483.0K | 16.6M | 1.30M | 118.0K | 9.72M | 1.04M |
| Cost of revenue | 460.0K | 824.0K | 1.42M | 1.86M | 1.78M | 32.1M | 14.1M | 14.1M | 13.1M | 13.7M |
| Gross profit | -460.0K | 500.0K | -1.42M | 27.0M | -483.0K | -15.5M | 1.30M | 118.0K | -3.36M | -12.6M |
| Research and development | 3.29M | 0 | 1.42M | 19.8M | 49.0M | 32.1M | 19.3M | 14.1M | 13.1M | 13.7M |
| Selling, general and administrative | 6.83M | 5.45M | 12.7M | 10.9M | 13.1M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M |
| Operating income | -4.23M | -12.2M | -15.0M | -1.83M | -62.5M | -25.4M | -26.6M | -21.8M | -10.4M | -16.2M |
| Depreciation and amortization | 242.0K | 28.0K | 634.0K | 1.16M | 1.12M | 766.0K | 392.0K | 358.0K | 232.0K | 180.0K |
| EBITDA | -3.99M | -12.2M | -14.4M | -668.0K | -61.4M | -24.7M | -26.2M | -21.5M | -10.2M | -16.0M |
| Interest expense | 1.00K | 18.0K | 0 | 595.0K | 1.69M | 573.0K | 786.0K | 672.0K | 795.0K | 724.0K |
| Income before tax | -5.58M | -9.69M | -16.9M | -2.37M | -64.1M | -24.7M | -26.3M | -22.4M | -12.0M | -16.9M |
| Income tax | -634.0K | 8.00K | 0 | 209.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -4.95M | -9.70M | -16.9M | -2.58M | -64.1M | -24.7M | -26.3M | -22.4M | -11.0M | -16.9M |
| Earnings per share, basic | -0.79 | -4.75 | -10.55 | -0.56 | -21.70 | -0.28 | -0.46 | -0.54 | -1.09 | -149.37 |
| Earnings per share, diluted | -0.79 | -4.75 | -10.55 | -0.56 | -21.70 | -0.28 | -0.46 | -0.54 | -1.09 | -149.37 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.75M | 12.5M | 816.0K | 8.58M | 34.6M | 33.3M | 48.5M | 26.3M | 25.8M | 19.6M |
| Short-term investments | 0 | 4.50M | 48.8M | 62.3M | 0 | |||||
| Receivables | 58.0K | 521.0K | 250.0K | 111.0K | 0 | 11.0K | 16.0K | 0 | 0 | 15.0K |
| Inventory | -250.0K | 510.0K | 3.03M | 646.0K | 646.0K | |||||
| Current assets | 4.62M | 13.7M | 2.02M | 10.1M | 43.7M | 86.3M | 112.8M | 27.7M | 27.6M | 20.0M |
| Property, plant and equipment | 306.0K | 26.0K | 54.0K | 2.53M | 3.93M | 4.12M | 2.10M | 1.06M | 1.32M | 503.0K |
| Goodwill | 4.40M | 0 | ||||||||
| Total assets | 14.0M | 15.1M | 11.6M | 23.3M | 64.9M | 100.4M | 115.3M | 28.8M | 29.0M | 20.6M |
| Accounts payable | 1.69M | 1.03M | 1.63M | 361.0K | 3.41M | 1.87M | 1.81M | 500.0K | 1.05M | 509.0K |
| Current liabilities | 3.89M | 3.07M | 2.51M | 1.64M | 34.1M | 13.7M | 31.1M | 2.04M | 3.36M | 12.2M |
| Long-term debt | 0 | 16.6M | 0 | 4.92M | 4.86M | 4.45M | ||||
| Total debt | 176.0K | 5.93M | 0 | 0 | 6.87M | 16.6M | 4.96M | 4.92M | 4.86M | 5.67M |
| Total liabilities | 10.1M | 8.28M | 8.55M | 8.41M | 53.6M | 38.9M | 34.5M | 7.80M | 9.01M | 18.1M |
| Shareholders' equity | 3.93M | 6.77M | 3.03M | 14.9M | 11.2M | 61.5M | 80.7M | 21.0M | 20.0M | 2.45M |
| Shares outstanding | 6.37M | 6.03M | 1.83M | 4.97M | 3.63M | 87.7M | 86.1M | 44.4M | 39.3M | 131.6K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.55M | -2.91M | -10.4M | -35.7M | -34.8M | -39.3M | 1.32M | -19.5M | -19.8M | -5.05M |
| Capital spending | -1.00K | 0 | 0 | -10.0K | -968.0K | -3.17M | -1.08M | -94.0K | -926.0K | -394.0K |
| Free cash flow | -8.56M | -2.91M | -10.4M | -35.7M | -35.8M | -42.4M | 235.0K | -19.6M | -20.7M | -5.44M |
| Cash from investing | -1.81M | 0 | -1.08M | 4.70M | 43.1M | 10.1M | -63.4M | -94.0K | -926.0K | -394.0K |
| Cash from financing | 1.60M | 13.4M | 3.67M | -3.10M | 1.12M | 15.1M | 84.3M | 20.1M | 26.9M | 6.34M |
| Share buybacks | -800.0K | -4.00K | -14.0K | 3.34M | 90.8M | 22.0M | 31.6M | 483.0K | ||
| Change in cash | -8.76M | 10.5M | -7.76M | -34.1M | 9.38M | -14.0M | 22.2M | 504.0K | 6.14M | 892.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 20, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 16, 2026 | Explanation request | SEC |
| DEF 14A · Proxy statement | Nov 12, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Nov 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 17, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 30, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 29, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 8-K · Current report | Apr 10, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 17, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 10, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 8-K · Current report | Nov 10, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Sep 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 29, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Sep 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 22, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 9, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 23, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 17, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Jun 27, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| NT 10-Q · Late filing notice | May 15, 2025 | Explanation request | SEC |
| 8-K · Current report | May 6, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 14, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 26, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 8-K · Current report | Mar 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 21, 2025 | Material contract | SEC |
| 8-K/A · Current report, amended | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 22, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 26, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Dec 26, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Dec 23, 2024 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Material contract | SEC |
| DEF 14A · Proxy statement | Dec 2, 2024 | Meeting notice | SEC |
| SC 13D · Big-stake notice | Nov 29, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Nov 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Sep 30, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 13, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 8-K · Current report | Aug 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Jul 30, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 19, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 25, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Jun 17, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 17, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Jun 11, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 11, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Jun 6, 2024 | Annual report | SEC |
| 8-K · Current report | Jun 6, 2024 | Results | SEC |
| 10-Q/A · Quarterly report, amended | Jun 6, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Jun 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 16, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2024 | Results | SEC |
| 10-Q/A · Quarterly report, amended | May 16, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | May 16, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Apr 22, 2024 | Current report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2023 | Current report | SEC |
| 8-K · Current report | Nov 28, 2023 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2023 | Explanation request | SEC |
| 8-K · Current report | Oct 6, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 13, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 31, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 23, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Aug 18, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 8-K · Current report | Aug 9, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 7, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Aug 4, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Jul 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 14, 2023 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 28, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 6, 2023 | Current report | SEC |
| 8-K · Current report | Jun 1, 2023 | Management or board change | SEC |
| 8-K · Current report | May 26, 2023 | Current report | SEC |
| 4 · Change in ownership | May 25, 2023 | Insider trade | SEC |
| 8-K · Current report | May 19, 2023 | Current report | SEC |
| 8-K · Current report | May 18, 2023 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | May 16, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 15, 2023 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | May 15, 2023 | Insider trade | SEC |
| NT 10-Q · Late filing notice | May 15, 2023 | Explanation request | SEC |
| 8-K · Current report | May 11, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | May 9, 2023 | Insider trade | SEC |
| 8-K · Current report | May 9, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | May 5, 2023 | Insider trade | SEC |
| 8-K · Current report | May 4, 2023 | Current report | SEC |
| 8-K · Current report | May 2, 2023 | Management or board change | SEC |
| 10-K/A · Annual report, amended | May 1, 2023 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | May 1, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Apr 27, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 13, 2023 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2023 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 9, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 2, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Mar 2, 2023 | Management or board change | SEC |
| 8-K · Current report | Feb 24, 2023 | Management or board change | SEC |
| 8-K · Current report | Feb 21, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Dec 19, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 19, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Dec 16, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Dec 14, 2022 | Meeting notice | SEC |
| 8-K · Current report | Dec 14, 2022 | Current report | SEC |
This page holds 200 of 537 filings. Open Filings
Cap table
Built by 6ix from Exicure, Inc.’s releases · as of Nov 18, 2026
- Common shares
- 6,545,995
- Fully diluted
- 6,545,995
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,545,995 | Nov 18, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 18, 2026 | 6,545,995 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David R Walt Other companies: Quanterix Corporation (Director · Since at least Dec 6, 2017); Dare Bioscience, Inc. (Director · Feb 23, 2015 – Jan 3, 2017 · Past); Illumina, Inc. (Director · Apr 2, 2007 – Apr 7, 2016 · Past) | Director · Sep 26, 2017 – Jun 4, 2020 · Past |
| Bali Muralidhar Other companies: Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020); OnKure Therapeutics, Inc. (Director · Apr 8, 2021 – Jun 6, 2023 · Past) | Director · Jun 2, 2021 – Jun 13, 2022 · Past |
| Chad A Mirkin Other companies: Nanosphere Inc (Director · Oct 31, 2007 – Feb 21, 2013 · Past) | Director · Sep 26, 2017 – Jun 12, 2020 · Past |
| David Snyder Other companies: Coya Therapeutics, Inc. (Chief Financial Officer & Chief Operating Officer · Since at least Dec 28, 2022) | Chief Financial Officer · Mar 12, 2020 – Mar 12, 2020 · Past |
| Aejin Hwang | Director · Since at least Sep 8, 2025 |
| Andy Yoo | Chief Restructuring Officer, Director · Nov 21, 2024 – Nov 21, 2024 · Past |
| Changil Ahn | Director · Feb 24, 2023 – Feb 24, 2023 · Past |
| Chang Keun Choi | Director · Dec 19, 2024 – Dec 19, 2024 · Past |
| Matthias Schroff | Chief Executive Officer, Director · Apr 16, 2018 – May 16, 2022 · Past |
| Min Woo Kang | Director · Dec 19, 2024 – Dec 19, 2024 · Past |
All 13 people
| Person | Seat |
|---|---|
| Sang Wook Song | Director · Dec 19, 2024 – Dec 19, 2024 · Past |
| Seung Ik Baik | Director · Nov 21, 2024 – Nov 21, 2024 · Past |
| Uh Kang Paul Sung | Director · Feb 24, 2023 – Feb 24, 2023 · Past |
Log in to ask 6ix AI your own questions about Exicure, Inc.